IL-2 fused with tumor-associated antigen (TAA)-targeted antibodies has been exploited, and these drugs can be classified into two main categories: cell-surface antigens, including epithelial cell adhesion molecule (EpCAM), ganglioside D2 (GD2), CD20, and carcinoembryonic antigen (CEA), and tumor extracellular matrix (ECM) targets, such as angiogenesis-related extra domain A/B (EDA/EDB) of fibronectin, tenascin-C, and collagen. Here, IL2 is linked to neoplasm.